Ithaka Group LLC Biomarin Pharmaceutical Inc Transaction History

Ithaka Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$84.2 - $98.62 $4.33 Million - $5.07 Million	-51,407 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $226,235 - $299,435	-2,823 Reduced 5.21%	51,407 $4.38 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $412,872 - $464,745	-4,396 Reduced 7.5%	54,230 $5.26 Million
Q2 2018 Aug 13, 2018	SELL	$76.01 - $99.03 $77,150 - $100,515	-1,015 Reduced 1.7%	58,626 $5.52 Million
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $4.63 Million - $5.52 Million	59,628 Added 458676.91%	59,641 $4.84 Million
Q4 2017 Feb 06, 2018	SELL	$80.76 - $95.13 $4.99 Million - $5.87 Million	-61,751 Reduced 99.98%	13 $5.37 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $4.98 Million - $5.86 Million	61,764	61,764 $5.75 Million

631

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ithaka Group LLC, based on Form 13F filings with the SEC.

Stay updated on Ithaka Group LLC with notifications on news.